Emcure Pharmaceuticals

• Solid Dosage facility at Hinjawadi - In 2006, Emcure received US FDA approval for its solid dosages facility at Hinjwadi, Pune. The plant manufactures solid oral formulations for the international regulated markets.
• Small volume parenteral facility at Hinjawadi - US FDA, UK MHRA approved. Has lyophilization and pfs capability
• Oncology injectable facility at Hinjawadi
• Solid Orals facilities at Jammu and Bhosari
• API facility at Kurkumbh- USFDA approved
• Biotech facility at Hinjawadi
• R&D center at gandhinagar and plant at sanand Ahmedabad.- Sanand facility is US FDA approved

USA - The company has a manufacturing facility and R&D center at East Brunswick, New Jersey, USA.

Emcure is planning to raise money through an initial public offering for some time now [5] In 2014, Blackstone sold its stake in Emcure to Bain Capital [6]

In 2010, Pfizer had to recall three batches of an anti-bacterial product from the US market due to presence of Bacillus anthracis, Penicillium chrysogenum & E. coli in some samples.[7] Teva recalled several batches of two products due to white tablets showing presence of Yersinia pestis in 2011.[8]

Emcure voices its concerns on HIV/AIDS through its "Let's fight AIDS together" initiative and supplies Antiretroviral drugs to Africa, Asia Pacific and CIS. As a part of its corporate social responsibility it supports 'Taal', a pharmacy for HIV/AIDS patients run by HIV/AIDS patients.

Emcure has license agreements with Bristol-Myers Squibb for Atazanavir [9] and Gilead Sciences for Tenofovir [10] as part of their Global Access Programs.

Roche has signed a deal with Emcure for manufacturing its blockbuster anticancer drugs Herceptin and Mabthera in India.[11] Under this programme the cancer drugs shall be made available to the developing world at an affordable 'cut-price' version.[12]

Heritage Pharmaceuticals, a division of Emcure has entered into a deferred prosecution agreement [13] with the United States Department of Justice, Antitrust Division ("DOJ") relating to a one-count Information for a conspiracy involving glyburide. In conjunction with the DPA, Heritage will pay a $225,000 fine.

In addition, the Company separately agreed to a settlement with the United States Department of Justice, Civil Division to resolve potential civil liability under the False Claims Act in connection with the antitrust conduct. Under the terms of the settlement, the Company has agreed to pay $7.1 million. Heritage has agreed to pay $7.1 million as part of a settlement with DOJ's Civil Division to resolve allegations of selling drugs at the artificially inflated prices, which resulted in claims submitted to or purchases by federal healthcare programs

• Emcure website